Acadia Pharmaceuticals reported a significant beat for the third quarter of 2026, with total revenues of $342.3 million compared to expectations of $268.4 million. The company's performance was propelled by the Rett syndrome treatment Daybue, which saw sales grow 39% year-over-year. Consequently, Acadia raised its full-year 2026 sales guidance for Daybue and reported a net income of $54 million, or $0.31 per diluted share.
Key Highlights
- Daybue net sales reached $140.1 million, exceeding the analyst estimate of $95.2 million by 47%, driven by the launch of Daybue STIX and international expansion.
- Nuplazid net sales grew 12% year-over-year on an adjusted basis to $202.2 million, supported by steady commercial reach in Parkinson’s disease psychosis.
- Full-year 2026 guidance for Daybue sales was raised to a range of $505 million to $520 million, up from the prior floor of $480 million.
- The clinical pipeline reached a milestone with positive Phase 2 RADIANT study results for remlifanserin, enabling a planned Phase 3 transition for Alzheimer's disease psychosis.